POTS and autonomic dysfunction — what your heart rate is telling you

This is postural orthostatic tachycardia syndrome — POTS — and the experience it produces is one of the more disorienting mismatches between how you feel and what medicine can see on a standard workup. Your EKG may be normal. Your echocardiogram may be normal. Your blood pressure may hold at normal values even while your heart rate climbs. The problem isn't cardiac anatomy. It's autonomic regulation — the nervous system's capacity to manage blood flow distribution and heart rate moment-to-moment as the body changes position and demands change. In POTS, that management is broken.

The diagnosis of POTS requires a sustained increase in heart rate of 30 beats per minute or more (40 bpm in adolescents) within ten minutes of standing, without a corresponding drop in blood pressure, along with symptoms of orthostatic intolerance. Formal diagnosis typically involves a tilt table test or a NASA lean test. But many patients spend years between onset and diagnosis, passed between cardiologists who find nothing structurally wrong, neurologists who run normal MRIs, and emergency rooms where a heart rate of 130 while sitting doesn't trigger the response it looks like it should.

The population most affected is young to middle-aged women, though POTS affects people of all ages and genders. Before 2020, it was a relatively obscure condition known primarily to autonomic specialists and the community of patients who had been living with it. Then long COVID dramatically changed its visibility. Estimates suggest that 2–14% of long COVID patients develop POTS or POTS-like dysautonomia after infection, and the sudden inclusion of this condition in mainstream clinical conversation has accelerated research, expanded specialist availability, and validated the experience of patients who had been dismissed for years.

The underlying biology of POTS is not uniform — different patients appear to have different mechanisms producing similar presentations. Hypovolemia (reduced blood volume) is present in many POTS patients; the normal compensatory mechanism for rising from a seated position involves vasoconstriction in the lower body to prevent blood pooling, and when blood volume is already low, this compensation is inadequate. Neuropathic POTS involves a partial failure of small-fiber sympathetic neurons in the lower extremities that normally mediate this vasoconstriction — the denervation means blood pools in the legs upon standing and the heart races to compensate for the reduced return. Hyperadrenergic POTS is characterized by excessive sympathetic activation — elevated norepinephrine upon standing, markedly elevated heart rate, and sometimes elevated blood pressure — and has a different management approach than the volume-depletion forms.

The mast cell overlap matters here. Patients with MCAS (mast cell activation syndrome) have a significantly elevated rate of POTS, and patients with POTS have elevated rates of MCAS. The mechanism is hypothesized to involve histamine's vasodilatory effects — released by activated mast cells, histamine dilates blood vessels and worsens the venous pooling and cardiovascular instability of POTS — as well as direct effects of mast cell mediators on autonomic neurons. In the long COVID POTS population, the mast cell intersection appears to be particularly prevalent, with a substantial fraction of patients having both presentations simultaneously.

Connective tissue hypermobility adds another layer. Hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) co-occur with POTS at rates far above chance — estimated at 40% or more in some POTS cohorts. The hypothesized mechanism involves the connective tissue laxity affecting blood vessel compliance and structure, impairing normal vasoconstriction, and compressing the autonomic nerve fibers that travel through connective tissue. Patients with this triad — hypermobility, POTS, and MCAS — represent one of the more complex presentations in functional medicine and require multidisciplinary evaluation.

The exercise intolerance of POTS is one of its most disabling features and one of the most misunderstood. It isn't deconditioning in the ordinary sense. The problem is that any upright exercise — walking, cycling upright, weight training with the upper body — requires the cardiovascular system to maintain perfusion while simultaneously managing orthostatic stress. For a POTS patient, that combination can trigger heart rates that produce symptoms and crash recovery that can last days. This is why POTS rehabilitation protocols have specific recommendations about beginning exercise in the recumbent or supine position — rowing machines, recumbent bikes, swimming — before gradually transitioning to upright activity. "Just exercise more" is not a POTS recommendation. Autonomic conditioning programs that are explicitly designed for dysautonomia, pacing the progression carefully, are.

The conventional management of POTS addresses several of the underlying mechanisms. Salt and fluid loading — increasing sodium intake to 10–12 grams daily and fluid to 2–3 liters — expands blood volume and reduces the volume-depletion component. Compression garments, particularly abdominal binders and compression stockings, reduce lower-body venous pooling. Beta-blockers (propranolol being commonly used) reduce the heart rate response to standing and can reduce symptom severity, though they're not appropriate for all subtypes. Ivabradine, an If-channel blocker that reduces heart rate without the negative inotropic effects of beta-blockers, has become a common choice particularly for younger patients. Midodrine, an alpha-1 agonist, increases peripheral vascular tone and is particularly useful for the neuropathic and hypovolemic subtypes. Fludrocortisone, a mineralocorticoid, promotes salt and water retention to expand blood volume. None of these is a cure; they're management tools that reduce symptom burden while the underlying condition — and the rehabilitation work — are addressed.

The peptide research conversation in POTS is less developed than in many of the other conditions in this category, and honest framing requires acknowledging that upfront. There are mechanistically plausible applications, but the clinical evidence is preliminary and POTS-specific research is sparse.

VIP — vasoactive intestinal peptide — has the most direct mechanistic relevance. VIP functions as a neuromodulator in the autonomic nervous system, affecting both sympathetic and parasympathetic signaling, and has demonstrated effects on vascular tone and autonomic balance in research contexts. Given the autonomic dysregulation at the core of POTS, VIP's regulatory role makes it mechanistically interesting. Some clinicians working with post-COVID autonomic dysfunction have incorporated VIP into protocols, particularly for patients with the mast-cell-activation overlap, where VIP's mast-cell-stabilizing properties add a second relevant mechanism. The clinical evidence for VIP in POTS specifically is observational and limited. It is a compounded peptide — not FDA-approved for POTS — and its use in this context is off-label and specialist-supervised.

Selank, the synthetic anxiolytic peptide studied primarily in Russian research for anxiety and stress regulation, enters the POTS conversation through the sympathetic overdrive angle. In hyperadrenergic POTS — the subtype characterized by excessive sympathetic activation — anything that modulates sympathetic nervous system tone is potentially relevant. Selank's hypothesized effects on neuropeptide Y and GABA-system activity suggest a mechanism that might reduce sympathetic hyperactivation, which in hyperadrenergic POTS is the proximal driver of symptoms. This is a mechanistic hypothesis extrapolated from research in other contexts, not a clinical finding in POTS populations. The evidence base is limited and the Western replication of Russian Selank research is insufficient to draw strong conclusions.

Mitochondrial peptides and NAD+ support appear in POTS discussions primarily through the exercise intolerance and fatigue component. MOTS-c and other mitochondria-derived peptides that influence metabolic flexibility and cellular energy production may help support the energy demands of rehabilitation programs, particularly for patients whose exercise capacity is severely limited by both fatigue and dysautonomia. The evidence in POTS specifically is theoretical. The supporting biology from mitochondrial function research in other fatigue conditions is the basis for the hypothesis.

The foundational interventions carry the evidence that the peptide conversation currently lacks. Salt and fluid protocols — consistently and rigorously followed — produce meaningful symptom reduction for most hypovolemic and neuropathic POTS patients. Compression is underutilized by patients who resist it for practical or aesthetic reasons and overperforms relative to the effort of compliance. Autonomic conditioning programs, when followed in the right sequence (recumbent first, progression gradual, pacing maintained), have demonstrated improvements in heart rate variability and symptom burden over months to years. Identifying and addressing comorbidities — MCAS, gut dysbiosis, sleep-disordered breathing, nutrient deficiencies — removes variables that sustain the autonomic dysfunction. These aren't adjunctive to treatment. They are the treatment, and anything else is adjunctive to them.

POTS requires specialist evaluation. A cardiologist familiar with dysautonomia, an autonomic specialist, or a neurologist with dysautonomia expertise are the appropriate first contacts. The evaluation should include a formal assessment of POTS subtype, because neuropathic, hypovolemic, and hyperadrenergic POTS have different management approaches and different peptide-relevant mechanisms. If MCAS is suspected, an allergist/immunologist with MCAS experience adds a critical layer. If hypermobility is part of the presentation, a rheumatologist or geneticist familiar with hEDS completes the picture. POTS is not typically a single-specialist condition in patients with significant symptom burden.

The acceleration of long COVID has produced a larger and more engaged specialist community for POTS than existed five years ago. Post-COVID clinics at academic medical centers have developed protocols that address autonomic dysfunction explicitly. Advocacy organizations including Dysautonomia International maintain provider directories and research resources. The infrastructure for POTS evaluation has improved, though it remains insufficient relative to patient need.

What your heart rate is telling you when it climbs to 140 just from standing is not that you are anxious, not that you are deconditioned, and not that there's nothing wrong. It's telling you that the autonomic management system that most people never have to think about is not working the way it's supposed to. That system can be evaluated, characterized, and addressed — imperfectly, incrementally, but meaningfully — with the right clinical team.